About
Sten Verland is a venture partner and founding partner at Sunstone Life Science Ventures who brings experience in executive management, venture capital, and pharmaceutical development. He holds a PhD in Immunology and has served as a CEO, board member, and chairman across biotech and pharmaceutical companies, with expertise in drug development, M&A, and fundraising. Verland also participates in innovation funding committees supporting early-stage life science ventures.
Experience
- Sunstone Life Science VenturesVenture Partner (founding partner)current2024 — presentCopenhagen Metropolitan Area
- Sunstone Life Science VenturesGeneral Partner (founding partner)2007 — 2024Copenhagen Metropolitan Area
- Verland - Life Science Venture & ConsultingCEO & Ownercurrent1994 — presentCopenhagen Metropolitan Area
- Minervax ApSNon Executive Directorcurrent2014 — presentCopenhagen Metropolitan Area
- Minervax ApSChair of the Audit Committeecurrent2020 — presentCopenhagen Metropolitan Area
- Sulis TherapeuticsChair of the Board of Directorscurrent2026 — presentAarhus, Central Denmark Region, Denmark
- Proxi BiotechChair of the Board of Directorscurrent2025 — presentCoopenhagen, Denmark
- Innovation Fund DenmarkMember of the InnoFounder selection committeecurrent2014 — presentCopenhagen Metropolitan Area
- Innovation Fund DenmarkMember of the InnoExplorer selection committee2019 — 2024Copenhagen Metropolitan Area
- Innovation Fund DenmarkMember of the InnoBooster selection committee2018 — 2021Copenhagen Metropolitan Area
- Skovlyst Production A/SNon Executive Directorcurrent2018 — presentCopenhagen Metropolitan Area
- Skovlyst Production A/SPrivate investor (through Verland Capital ApS)current2009 — presentCoopenhagen, Denmark
- The Research Council of NorwayPanel Member2020 — 2025Oslo, Norway
- Neumirna TherapeuticsChair of the Board of Directors2022 — 2025Copenhagen Metropolitan Area
- Anergis SANon Executive Director2011 — 2024Lausanne, Vaud, Switzerland
- Stipe TherapeuticsMember of the Audit Committee2019 — 2024Aarhus, Central Denmark Region, Denmark
- Stipe TherapeuticsNon Executive Director2019 — 2024Aarhus, Central Denmark Region, Denmark
- Vaximm AGBoard Observer2019 — 2022Basel, Switzerland
- Vaximm AGNon Executive Director2011 — 2019Basel, Switzerland
- OxTheraNon Executive Director2016 — 2022Greater Stockholm Metropolitan Area
Education
- Københavns Universitet - University of CopenhagenDoctor of Philosophy - PhD, Immunology1988 — 1990
- Københavns Universitet - University of CopenhagenMaster of Science - MSc, Biology and Mathematics1979 — 1986
Skills & more
Venture Capital59Biotechnology45Entrepreneurship37Drug Development19Lifesciences19Mergers9Business Strategy12Immunology12Corporate Development9Mergers & Acquisitions8R&D6Clinical Development5
+12 more
StrategyExecutive ManagementPrivate EquityPharmaceutical IndustryAngel InvestingVenture FinancingClinical TrialsIPONegotiationAdvisory BoardsStart-upsCommercializationLanguages Danish · English · German · Other Scandinavian languages
From Sten's professional profile.
Same school
Also attended Københavns Universitet - University of Copenhagen77
Jesper GromadaInvestor at Third Rock VenturesTommy AhlersFormer Danish Science Minister at Giant Ventures Global LlpClaus AnderssonGeneral Partner at Sunstone CapitalSophie Blomgren-HansenStudent Assistant at Sunstone CapitalTine LindgreenPrincipal at SEED Capital DenmarkAnne Cathrine WilhjelmAttorney, Partner at SEED Capital Denmark
+ 71 more
Shared employers
Also worked at OxThera1
Also worked at Department of Clinical Chemistry, Bispebjerg Hospital, Copenhagen3
Colleagues at Sunstone Capital
Claus Andersson
General Partner at Sunstone Capital
Kartik Kashyap
Student Assistant at Sunstone Capital
Line Jacobsen
Management Assistant at Sunstone Capital
Merete Lundbye Moller
Venture Partner, General Counsel at Sunstone Capital
Merete Lundbye Møller
Venture Partner, General Counsel at Sunstone Capital
Michael Jones
General Partner at Sunstone Capital
Ravi Sharma
Managing Director at Sunstone Capital
Robert Cobuzzi
Venture Partner at Sunstone Capital
















